REFERENCES
- Thompson JC, Wood J, Feuer D. Prostate cancer: palliative care and pain relief. Br Med Bull. 2007;83:341–354.
- Goodin S, Rao KV, DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist. 2002;7:360–370.
- Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–176.
- Chang SS. Treatment options for hormone-refractory prostate cancer. Rev Urol. 2007;9(Suppl 2):S13–S18.
- Eisenberger MA, Carducci MA. Chemotherapy for hormone-resistance prostate cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology. Philadelphia: WB Saunders; 2007:3101–3117.
- Smith JA Jr, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology. 1999;54(6A Suppl):8–14.
- Crawford ED, Rosenblum M, Ziada AM, Lange PH. Hormone refractory prostate cancer. Urology. 1999;54(6A Suppl):1–7.
- Hoang BX, Levine SA, Shaw DG, Tran DM, Tran HQ, Nguyen PM, Tran HD, Hoang C, Pham PT. Dimethyl sulfoxide as an excitatory modulator and its possible role in cancer pain management. Inflamm Allergy Drug Targets. 2010;9:306–312.
- Hoang BX, Tran DM, Tran HQ, Nguyen PT, Pham TD, Dang HV, Ha TV, Tran HD, Hoang C, Luong KN, Shaw DG. Dimethyl sulfoxide and sodium bicarbonate in the treatment of refractory cancer pain. J Pain Palliat Care Pharmacother. 2011;25:19–24.